A Prospective Study Comparing Human Metapneumovirus with Other Respiratory Viruses in Adults with Hematologic Malignancies and Respiratory Tract Infections

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2581, USA.
The Journal of Infectious Diseases (Impact Factor: 6). 10/2005; 192(6):1061-5. DOI: 10.1086/432732
Source: PubMed


Human metapneumovirus (hMPV) is a recently described paramyxovirus associated with upper and lower respiratory-tract infection (URI and LRI, respectively). We conducted a prospective study of URI and LRI in adults with hematologic malignancies during a 4-year period. We retrospectively tested samples by reverse-transcription polymerase chain reaction for hMPV and analyzed clinical data. Twenty-two (9%) of 251 episodes of respiratory infection tested positive for hMPV. Sixteen (73%) of the illnesses occurred in hematopoietic stem-cell transplant recipients. Nine patients with hMPV developed LRI; 3 of these patients died. hMPV is a common cause of respiratory infections in adults with hematologic malignancies, with associated morbidity and mortality.

Download full-text


Available from: James E Crowe,
  • Source
    • "The efficacious prevention and treatment of HMPV infections have not been well described. Ribavirin and/or intravenous immunogloblin were used to treat HMPV pneumonia in several studies but the efficacy was not defined [26,180]. The prevention and treatment strategies of HRhV are limited by the lack of antiviral agents and clinical trials. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Viral infections are important causes of morbidity and mortality after allogeneic stem cell hematopoietic transplantation (allo-HSCT). Although most viral infections present with asymptomatic or subclinical manifestations, viruses may result in fatal complications in severe immunocompromised recipients. Reactivation of latent viruses, such as herpesviruses, is frequent during the immunosuppression that occurs with allo-HSCT. Viruses acquired from community, such as the respiratory and gastrointestinal viruses, are also important pathogens of post-transplant viral diseases. Currently, molecular diagnostic methods have replaced or supplemented traditional methods, such as viral culture and antigen detection, in diagnosis of viral infections. The utilization of polymerase chain reaction facilitates the early diagnosis. In view of lacking efficacious agents for treatment of viral diseases, prevention of viral infections is extremely valuable. Application of prophylactic strategies including preemptive therapy reduces viral infections and diseases. Adoptive cellular therapy for restoring virus-specific immunity is a promising method in the treatment of viral diseases.
    Journal of Hematology & Oncology 12/2013; 6(1):94. DOI:10.1186/1756-8722-6-94 · 4.81 Impact Factor
  • Source
    • "HMPV is related to respiratory syncytial virus (RSV), which is the most significant respiratory pathogen of infancy and early childhood. Epidemiologic studies showed that HMPV is associated with significant morbidity in infants and other high-risk populations, such as immunocompromised patients [2] [3] [4] [5]. Thus, HMPV is an important cause of hospitalizations, in the same way as the other respiratory viruses, RSV, parainfluenza virus or influenza virus [6]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human metapneumovirus (HMPV) is a paramyxovirus that causes acute respiratory-tract infections in children and adults worldwide. A safe and effective vaccine could decrease the burden of disease associated with this novel pathogen. We engineered HMPV viral-like particles (HMPV-VLPs) derived from retroviral core particles that mimic the properties of the viral surface of two HMPV viruses of either lineage A or B. These VLPs functionally display F and G HMPV surface glycoproteins. When injected in mice, HMPV-VLPs induce strong humoral immune response against both homologous and heterologous strains. Moreover, the induced neutralizing antibodies prevented mortality upon subsequent infection of the lungs with both homologous and heterologous viruses. Upon challenge, viral titers in the lungs of immunized animals were significantly reduced as compared to those of control animals. In conclusion, a HMPV-VLP vaccine that induces cross-protective immunity in mice is a promising approach to prevent HMPV infections.
    Vaccine 04/2013; 31(25). DOI:10.1016/j.vaccine.2013.03.051 · 3.62 Impact Factor
  • Source
    • "hMPV is now widely recognized as an opportunistic infection in immunocompromised hosts such as hematopoietic stem cell transplant (HSCT) and pulmonary transplant recipients, leading to a significant respiratory morbidity [6]. Although its detection is not yet routinely performed, hMPV appears to account for 9% of acute pneumonia in patients with haematologic malignancies (including HSCT), in a similar proportion to RSV [7]. This rate is close to that reported in lung transplant recipients, ranging from 6% to 12% of LRI [6] [8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human metapneumovirus (hMPV) is emerging as a cause of a severe respiratory tract infection in immunocompromised patients. hMPV pneumonia has only been seldom reported in nonpulmonary solid organ transplanted patients, such as renal transplant recipients. We report here a case of a 39-year-old patient presenting with fever, cough, and interstitial opacities on CT scan diagnosed as a nonsevere hMPV pneumonia 11 years after a renal transplantation. Infection resolved spontaneously. Differential diagnosis with Pneumocystis pneumonia was discussed. We review the medical literature and discuss clinical presentation and detection methods that can be proposed in solid organ transplant recipients.
    11/2012; 2012:353871. DOI:10.1155/2012/353871
Show more